-
New FIFA ruling boosts prospects for women coaches
-
Megan Jones to captain England in Women's Six Nations
-
Trump says told Netanyahu not to attack Iran gas fields
-
MLS reveals shortened 2027 campaign details
-
FIFA planning for World Cup to 'go ahead as scheduled' amid Iran uncertainty
-
Braves outfielder Profar's full MLB season ban upheld: report
-
Mideast war exposing Europe's reliance on Gulf flights, airlines warn
-
Ghalibaf: Iran's new strongman running war effort
-
UN shipping body urges 'safe maritime corridor' in Gulf
-
Venezuelan student freed after months in US immigration custody
-
Trump to Japan PM: 'Why didn't you tell me about Pearl Harbor?'
-
US mulls lifting sanctions on Iranian oil at sea despite war on Tehran
-
IMF raises concern over global inflation, output over Iran war
-
Middle East war weighs on global trade outlook: WTO
-
Cunningham out for NBA Pistons with collapsed lung
-
Belarus frees 250 political prisoners in US-brokered deal
-
Iran attacks on gas and oil refineries heighten fears over war fallout
-
Fernandez 'completely committed' to Chelsea insists Rosenior
-
Call to add Nazi camps to UNESCO list
-
England cricket chiefs to front up to media over Ashes flop
-
'Miracle': Europe reconnects with lost spacecraft
-
Nigeria 'challenged by terrorism', president says on UK state visit
-
Woltemade deployed too deep to be dangerous at Newcastle, says Nagelsmann
-
Wimbledon expansion plan gets legal boost
-
EU summit fails to rally Orban behind stalled Ukraine loan
-
New Morocco coach praises 'well-deserved' Cup of Nations decision
-
Senegal to appeal CAF Africa Cup of Nations decision
-
'Mixing things up': Nagelsmann goes for flexibility in new Germany squad
-
Record-setter Hodgkinson hopes 'fourth time lucky' at world indoors
-
Atletico target Romero says his focus on Spurs' survival bid
-
Karalis hits prime form to threaten Duplantis surprise
-
Freshly returned Mbappe leads France squad for Brazil, Colombia friendlies
-
US earns its lowest-ever score on freedom index
-
Europe's super elite teach English clubs a Champions League lesson
-
What we know about the UK's deadly meningitis outbreak
-
Karl handed Germany debut as Musiala misses out with injury
-
What cargo ships are passing Hormuz strait?
-
Bank of England holds interest rate amid Middle East war
-
Energy prices soar, Iran and US trade threats after Qatar gas hit
-
'Surreal' for F1 world champion Norris to have Tussauds waxwork
-
Iran hangs three men in first executions over January protests
-
North Korea, Philippines qualify for 2027 Women's World Cup
-
Man Utd boss Carrick expects hard test against resolute Bournemouth
-
Oil prices surge, stocks sink on energy shock fears
-
Alibaba pins hopes on AI as quarterly net profit drops
-
Oil soars 10% after Qatar energy sites hit in Mideast war
-
Defiant Orban digs in over blocked Ukraine loan at EU talks
-
Iran 'boycotting' USA but not World Cup: football federation chief
-
Tokyo's dazzling cherry blossom season officially begins
-
Energy prices surge, stocks sink amid rising energy shock fears
US medical agency will scale back testing on monkeys
The United States will scale back certain drug-safety testing requirements on monkeys, federal regulators said Tuesday, marking the latest step by President Donald Trump's administration to limit the use of animals in research.
Under new draft guidance from the Food and Drug Administration, computer models, lab-grown mini-organs, and human studies will replace the use of non-human primates in testing monoclonal antibodies -- lab-engineered proteins used to treat cancers, autoimmune conditions and other diseases.
"We are delivering on our roadmap commitment to eliminate animal testing requirements in drug evaluation and our promise to accelerate cures and meaningful treatments for Americans," FDA Commissioner Marty Makary said in a statement.
The statement added that typical nonclinical programs involving monoclonal antibodies could include more than 100 macaque monkeys -- apes are no longer used in any invasive research in the US -- yet often do not yield human-approved treatments.
The move was welcomed by animal-advocacy groups.
Zaher Nahle, a former animal researcher who is now the senior scientific advisor for nonprofit Center for a Humane Economy, told AFP the move was an "important step."
"These primates are not reliable in terms of predicting the toxicity, so you can get at least equal or better results in terms of your accuracy in predicting toxicology using other approaches," he added.
What's more, he noted, studies show that more than 90 percent of drugs deemed safe and effective in animals fail to win approval for human use.
The FDA's announcement follows a report in the journal Science last month that the Centers for Disease Control and Prevention would close its primate labs.
It "moves us one step closer to wiping out the federal government's wasteful monkey business," Justin Goodman of White Coat Waste Project told AFP.
But the National Institutes of Health -- the country's primary biomedical research agency -- remains a notable "outlier," he added. According to public data, 7,700 primates are confined in federal government labs and breeding facilities, of which 6,700 are at NIH.
Advocates of animal research have pushed back.
"Poorly planned transitions -- including premature study termination -- can place animals at serious risk and may undermine years of scientific investment intended to strengthen public health preparedness and advance lifesaving medical progress," advocacy group Americans for Medical Progress said after the CDC news was reported.
Proponents of animal testing say the research has been indispensable for major medical advances, including vaccines for diphtheria, yellow fever, measles and Covid-19.
Critics counter that decades-old laws have created regulatory lock-in, that publication incentives reward animal studies in top journals, and that a lucrative "animal-industrial complex" has helped entrench the status quo.
D.Schneider--BTB